Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
The aim of the work is to study the immunogenicity, tolerability, and clinical efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Material and methods. The study included 61 patients with a confirmed diagnosis of SLE, including...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2020-08-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849693080825888768 |
|---|---|
| author | G. M. Tarasova B. S. Belov M. V. Cherkasova S. K. Soloviev E. A. Aseeva T. M. Reshetnyak T. V. Popkova N. M. Kosheleva |
| author_facet | G. M. Tarasova B. S. Belov M. V. Cherkasova S. K. Soloviev E. A. Aseeva T. M. Reshetnyak T. V. Popkova N. M. Kosheleva |
| author_sort | G. M. Tarasova |
| collection | DOAJ |
| description | The aim of the work is to study the immunogenicity, tolerability, and clinical efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Material and methods. The study included 61 patients with a confirmed diagnosis of SLE, including 53 women, 8 men, aged 19 to 68 years. The disease activity at the time of vaccination: in 9 patients — high, in 13 — medium, in 34 — low, in 5 — remission. Therapy outline: 59 patients received glucocorticoids (GC) 5–30 mg/day in terms of prednisolone, 45 — hydroxychloroquine (GC), 33 — cytostatics (CS), 22 — genetically engineered biological drugs (GEBD): 11 — rituximab (RTM), 10 — belimumab (BLM). 23-valent polysaccharide pneumococcal vaccine in an amount of 0.5 ml (1 dose) was injected subcutaneously. Follow-up period: 9 patients — 3 months, 52 — 1 year after the vaccination. Patients were examined before vaccination, as well as in 1, 3, and 12 months after the vaccination. Results and discussion. After a year of observation, the number of «responders» to vaccination was 61.5%, «non-responders» — 38.5%. There was a decreased response to vaccine in patients receiving GEBD compared with patients who did not receive GEBD (40% and 75%, respectively), p=0.02. No differences were found against the background of RTM and BLM therapy. Administering GC in a dose exceeding 10 mg/day did not lead to a more significant decrease in response to vaccine compared to other patients. Standard local vaccination reactions of mild to moderate severity were noted in 50.8% of the patients, general reaction of mild severity — in 1 patient (1.6%), hyperergic Arthus-like reaction — in 1 patient (1.6%), the symptoms of which were relieved in 7 days. During the observation period (1 year), not a single case of exacerbation of SLE, reliably associated with the vaccination, was registered, and no new autoimmune phenomena were identified. Clinically positive dynamics was noted in the form of a decrease in the number of episodes of pneumonia, as well as acute and exacerbated chronic bronchitis, sinusitis. Conclusion. Sufficient immunogenicity, good tolerance, and clinical effectiveness of PPV-23 in patients with SLE, incl. those, who received combined immunosuppressive therapy. Further studies are needed in large groups of patients with long follow-up periods. |
| format | Article |
| id | doaj-art-e2902b05bee04265b4c5203a1755c09b |
| institution | DOAJ |
| issn | 0235-2990 |
| language | Russian |
| publishDate | 2020-08-01 |
| publisher | LLC "Publishing House OKI" |
| record_format | Article |
| series | Антибиотики и Химиотерапия |
| spelling | doaj-art-e2902b05bee04265b4c5203a1755c09b2025-08-20T03:20:32ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-08-01655-6354010.37489/0235-2990-2020-65-5-6-35-40728Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus ErythematosusG. M. Tarasova0B. S. Belov1M. V. Cherkasova2S. K. Soloviev3E. A. Aseeva4T. M. Reshetnyak5T. V. Popkova6N. M. Kosheleva7Scientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationScientific Research Institute of Rheumatology named after V. A. Nasonova of the Ministry of Health of the Russian FederationThe aim of the work is to study the immunogenicity, tolerability, and clinical efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Material and methods. The study included 61 patients with a confirmed diagnosis of SLE, including 53 women, 8 men, aged 19 to 68 years. The disease activity at the time of vaccination: in 9 patients — high, in 13 — medium, in 34 — low, in 5 — remission. Therapy outline: 59 patients received glucocorticoids (GC) 5–30 mg/day in terms of prednisolone, 45 — hydroxychloroquine (GC), 33 — cytostatics (CS), 22 — genetically engineered biological drugs (GEBD): 11 — rituximab (RTM), 10 — belimumab (BLM). 23-valent polysaccharide pneumococcal vaccine in an amount of 0.5 ml (1 dose) was injected subcutaneously. Follow-up period: 9 patients — 3 months, 52 — 1 year after the vaccination. Patients were examined before vaccination, as well as in 1, 3, and 12 months after the vaccination. Results and discussion. After a year of observation, the number of «responders» to vaccination was 61.5%, «non-responders» — 38.5%. There was a decreased response to vaccine in patients receiving GEBD compared with patients who did not receive GEBD (40% and 75%, respectively), p=0.02. No differences were found against the background of RTM and BLM therapy. Administering GC in a dose exceeding 10 mg/day did not lead to a more significant decrease in response to vaccine compared to other patients. Standard local vaccination reactions of mild to moderate severity were noted in 50.8% of the patients, general reaction of mild severity — in 1 patient (1.6%), hyperergic Arthus-like reaction — in 1 patient (1.6%), the symptoms of which were relieved in 7 days. During the observation period (1 year), not a single case of exacerbation of SLE, reliably associated with the vaccination, was registered, and no new autoimmune phenomena were identified. Clinically positive dynamics was noted in the form of a decrease in the number of episodes of pneumonia, as well as acute and exacerbated chronic bronchitis, sinusitis. Conclusion. Sufficient immunogenicity, good tolerance, and clinical effectiveness of PPV-23 in patients with SLE, incl. those, who received combined immunosuppressive therapy. Further studies are needed in large groups of patients with long follow-up periods.https://www.antibiotics-chemotherapy.ru/jour/article/view/738systemic lupus erythematosuspneumoniavaccination23-valent polysaccharide pneumococcal vaccineimmunosuppressive therapygenetically engineered biological drugs |
| spellingShingle | G. M. Tarasova B. S. Belov M. V. Cherkasova S. K. Soloviev E. A. Aseeva T. M. Reshetnyak T. V. Popkova N. M. Kosheleva Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus Антибиотики и Химиотерапия systemic lupus erythematosus pneumonia vaccination 23-valent polysaccharide pneumococcal vaccine immunosuppressive therapy genetically engineered biological drugs |
| title | Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus |
| title_full | Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus |
| title_fullStr | Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus |
| title_full_unstemmed | Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus |
| title_short | Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus |
| title_sort | immunogenicity tolerability and clinical effectiveness of 23 valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus |
| topic | systemic lupus erythematosus pneumonia vaccination 23-valent polysaccharide pneumococcal vaccine immunosuppressive therapy genetically engineered biological drugs |
| url | https://www.antibiotics-chemotherapy.ru/jour/article/view/738 |
| work_keys_str_mv | AT gmtarasova immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT bsbelov immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT mvcherkasova immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT sksoloviev immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT eaaseeva immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT tmreshetnyak immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT tvpopkova immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus AT nmkosheleva immunogenicitytolerabilityandclinicaleffectivenessof23valentpolysaccharidepneumococcalvaccineinpatientswithsystemiclupuserythematosus |